论文部分内容阅读
Background Statins reduce adverse cardiovascular outcomes and slow the progression of coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) cholesterol. However, few studies have either assessed the ability of intensive statin treatments to achieve disease regression or compared alternative approaches to maximal statin administration. Methods We performed serial intravascular ultrasonography in 1039 patients with coronary disease, at baseline and after 104 weeks of treatment with either atorvastatin, 80 mg daily, or rosuvastatin, 40 mg daily, to compare the effect of these two intensive statin regimens on the progression of coronary atherosclerosis, as well as to assess their safety and side-effect profiles. Results After 104 weeks of therapy, the rosuvastatin group had lower levels of LDL cholesterol than the atorvastatin group (62.6 vs. 70.2 mg per deciliter [1.62 vs. 1.82 mmol per liter], P < 0.001), and higher levels of high-density lipoprotein (HDL) cholesterol (50.4 vs. 48.6 mg per deciliter [1.30 vs. 1.26 mmol per liter], P = 0.01). The primary efficacy end point, percent atheroma volume (PAV), decreased by 0.99% (95% confidence interval [CI], 1.19 to-0.63) with atorvastatin and by 1.22% (95% CI, -1.52 to -0.90) with rosuvastatin (P = 0.17). The effect on the secondary efficacy end point, normalized total atheroma volume (TAV), was more favorable with rosuvastatin than with atorvastatin:-6.39 mm3 (95% CI, -7.52 to -5.12), as compared with? 4.42 mm3 (95% CI, -5.98 to -3.26) (P = 0.01). Both agents induced regression in the majority of patients: 63.2% with atorvastatin and 68.5% with rosuvastatin for PAV (P = 0.07) and 64.7% and 71.3%, respectively, for TAV (P = 0.02). Both agents had acceptable side-effect profiles, with a low incidence of laboratory abnor- malities and cardiovascular events. Conclusions Maximal doses of rosuvastatin and atorvastatin resulted in significant regression of coronary atherosclerosis. Despite the lower level of LDL cholesterol and the higher level of HDL cholesterol achieved with rosuvastatin, a similar degree of regression of PAV was observed in the two treatment groups. (Funded by As-traZeneca Pharmaceuticals; ClinicalTrials.gov number, NCT000620542.)
Background Statins reduce adverse cardiovascular outcomes and slow the progression of coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) cholesterol. However, few studies have either assessed the ability of intensive statin treatments to achieve disease regression or compared alternative approaches Methods We performed serial intravascular ultrasonography in 1039 patients with coronary disease, at baseline and after 104 weeks of treatment with either ororvastatin, 80 mg daily, or rosuvastatin, 40 mg daily, to compare the effect of these two intensive statin Results After 104 weeks of therapy, the rosuvastatin group had lower levels of LDL cholesterol than the atorvastatin group (62.6 vs. 70.2 mg per deciliter [ 1.62 vs. 1.82 mmol per liter], P <0.001), and higher levels of high-density lipopro The primary efficacy end point, percent atheroma volume (PAV), decreased by 0.99% (95% confidence interval (50% vs. 48.6 mg per deciliter [1.30 vs. 1.26 mmol per liter], P = [CI], 1.19 to-0.63) with atorvastatin and by 1.22% (95% CI -1.52 to -0.90) with rosuvastatin (P = 0.17). The effect on the secondary efficacy end point, normalized total atheroma volume (TAV) , was more favorable with rosuvastatin than with atorvastatin: -6.39 mm3 (95% CI, -7.52 to -5.12), as compared with 4.42 mm3 (95% CI, -5.98 to -3.26) (P = 0.01). Both agents induced regression in the majority of patients: 63.2% with atorvastatin and 68.5% with rosuvastatin for PAV (P = 0.07) and 64.7% and 71.3%, respectively, for TAV (P = 0.02) with a low incidence of laboratory abnor- malities and cardiovascular events. Conclusions Maximal doses of rosuvastatin and atorvastatin resulted in significant regression of coronary atherosclerosis. DespiThe lower level of LDL cholesterol and the higher level of HDL cholesterol achieved with rosuvastatin, a similar degree of regression of PAV was observed in the two treatment groups. (Funded by As-traZeneca Pharmaceuticals; Clinical Trials.gov number, NCT000620542.)